DAIC

JANUARY 8, 2025

a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc.,

Blood Pressure 52

Blood Pressure Hypertension Kidney Disease BMI 52

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

DAIC

SEPTEMBER 11, 2024

Digital technologies may reveal it is even more common than the current analysis indicates. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC. Marcus, MD, MAS, a cardiologist and electrophysiologist at UCSF Health.

Atrial Fibrillation 92

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 92

Cardiometabolic Health Congress

JULY 25, 2024

Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The future of care demands a holistic approach.

Education 100

Education Innovation Risk Factors Obesity 100

Cardiometabolic Health Congress

OCTOBER 10, 2024

Eko : AI-powered heart sound and EKG sensors paired with FDA-approved software for heart disease monitoring. RenalytixAI : Provides AI-enabled diagnostic solutions for early detection and management of kidney disease. Viz.ai : Uses AI to enhance care coordination and improve outcomes in cardiovascular care.

Innovation 52

Innovation Technology Kidney Disease Chronic Disease 52

DAIC

JANUARY 19, 2024

milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. billion adults worldwide.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

Cardiometabolic Health Congress

JULY 17, 2024

Notes: Approved after initial rejection two years prior based on safety data from Japan, where the drug had been used since 2020 It can only be used in kidney disease patients on dialysis for at least 3 months. The label includes a “black box” warning for CV risk due to blood clots.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Defibrillator 59